Skip to main content
. 2022 Jan 7;37(4):e29. doi: 10.3346/jkms.2022.37.e29

Table 1. Baseline characteristics of the enrolled COVID-19-infected patients according to HBV infection with or without antiviral agent treatment.

Characteristics All patients (n = 19,160) HBV-infected (n = 675) Not HBV-infected (n = 18,485) P value Anti-viral agents user (n = 138) Anti-viral agents non-user (n = 537) P value
Age, yr 52.8 ± 12.5 59.3 ± 15.7 52.6 ± 21.7 < 0.001 58.5 ± 12.0 59.5 ± 16.5 0.170
Range < 0.001 0.009
≤ 39 5,604 (29.2) 80 (11.9) 5,524 (29.9) 10 (7.2) 70 (13.0)
40–65 7,695 (40.2) 355 (52.6) 7,340 (39.7) 88 (63.8) 267 (49.7)
≥ 65 5,861 (30.6) 240 (35.6) 5,621 (30.4) 40 (29.0) 200 (37.3)
Sex 0.290 0.017
Male 9,065 (47.3) 333 (49.3) 8,732 (47.2) 81 (58.7) 252 (46.9)
Female 10,095 (52.7) 342 (50.7) 9,753 (52.8) 57 (41.3) 285 (53.1)
Comorbidity
Diabetes mellitus 6,804 (35.5) 395 (58.5) 6,409 (34.7) < 0.001 71 (51.5) 324 (60.3) 0.066
Hypertension 7,239 (37.8) 336 (49.8) 6.903 (37.3) < 0.001 62 (44.9) 274 (51.0) 0.215
Cerebrovascular disease 3,001 (15.7) 141 (20.9) 2,860 (15.5) < 0.001 24 (17.4) 117 (21.8) 0.291
Chronic pulmonary disease 6,120 (31.9) 275 (40.7) 5,845 (31.6) < 0.001 41 (29.7) 234 (43.6) 0.003
Chronic renal disease 781 (4.1) 64 (9.5) 717 (3.9) < 0.001 8 (5.8) 56 (10.4) 0.105
Liver cirrhosis 377 (2.0) 129 (19.1)) 248 (1.3) < 0.001 64 (46.4) 65 (12.1) < 0.001
Cancer 2,947 (15.4) 311 (46.1) 2,636 (14.3) < 0.001 92 (66.7) 219 (40.8) < 0.001
Hepatocellular carcinoma 498 (2.6) 155 (23.0) 343 (1.9) < 0.001 67 (48.6) 88 (16.4) < 0.001

Data are shown as number (%) or mean ± SD. P values were calculated using the student’s t-test or the χ2 or Fischer exact test, as appropriate.

COVID-19 = coronavirus disease 2019, HBV = hepatitis B virus.